The Recovery Factor
Thymosin Beta-4 (fragment)
TB-500 is a synthetic version of Thymosin Beta-4, a 43-amino acid protein naturally present in virtually all human and animal cells. It plays a critical role in tissue repair, cell migration, blood vessel formation, and inflammation regulation. TB-500 has been extensively researched in wound healing, cardiac repair, and musculoskeletal recovery contexts.
TB-500 promotes healing primarily through its ability to regulate actin, a key protein involved in cell structure and movement. This enables cells to migrate to injury sites, form new blood vessels, and reduce inflammatory responses.
Sequesters and regulates actin polymerization, enabling cells to become more mobile and migrate efficiently to sites of injury.
Promotes angiogenesis (new blood vessel formation) in damaged tissue, restoring blood supply and oxygen delivery to healing areas.
Downregulates pro-inflammatory cytokines and reduces systemic inflammation, creating an environment conducive to healing.
Supports stem cell maturation and differentiation, enhancing the body's regenerative capacity at the cellular level.
Promotes hair follicle stem cell migration, which has led to research into its potential for hair regrowth applications.
Accelerates healing of wounds, including dermal, corneal, and cardiac tissue, by promoting cell migration and new blood vessel formation.
Significantly reduces inflammation through cytokine modulation, making it valuable for chronic inflammatory conditions and acute injury recovery.
Supports repair of muscle tissue following injury, with research showing improved recovery times and reduced scarring in muscle damage models.
Preclinical research shows potential for cardiac tissue regeneration following ischemic events, with improved cardiac function in animal models.
Thymosin Beta-4 promoted cardiac repair and improved survival after myocardial infarction in mouse models, activating epicardial progenitor cells.
TB-500 demonstrated significant wound healing acceleration with reduced inflammation and improved tissue organization in dermal wound models.
Thymosin Beta-4 eye drops improved corneal wound healing and reduced inflammation in human clinical studies for dry eye and corneal injuries.
TB-500 has shown a favorable safety profile in preclinical and limited clinical studies. As a naturally occurring protein, it is generally well-tolerated. The corneal formulation (RGN-259) has undergone Phase II clinical trials with positive safety data.
Research Status
Thymosin Beta-4 has a substantial body of preclinical evidence and limited but growing clinical data. The corneal formulation has completed Phase II trials. Musculoskeletal applications remain primarily in preclinical and observational stages.
Regulatory Note
TB-500 is not FDA-approved. The corneal formulation (RGN-259) is in clinical development. Available through compounding pharmacies with a physician prescription.